A large number of in vivo and in vitro studies have shown that miRNAs either inhibit translation, destabilize mRNA, or both. Further studies are required to investigate the contribution of miRNAs to SHBG regulation. In conclusion, our results in human prostate-derived cell lines indicate that SHBG TU-1A and TU-1B are translated from the first in-frame ATG found in the exon 2 sequence, and that their corresponding 59UTR exons downregulate SHBG translation. EOC comprises several subtypes of histopathologically different tumours. There is growing evidence for the existence of at least two distinct tumourigenetic pathways, corresponding to the development of type I and type II tumours. Type I tumours include highly differentiated serous carcinomas, mucinous carcinomas, endometroid carcinomas, clear cell carcinomas and malignant Brenner tumours. They are thought to arise from precursor lesions such as cystadenomas, borderline tumours or endometriosis and suggested to be a result of mutations in e.g. KRAS, BRAF, CTNNB1 or PTEN genes. Type II carcinomas include moderately and poorly differentiated serous carcinomas, carcinosarcomas and undifferentiated carcinomas, and appear to originate de novo from as yet no known identified precursor lesions, possibly resulting from mutations in e.g. TP53. Thus, ovarian carcinogenesis appears to be associated with abnormalities in multiple gene families. How these genetic alterations are reflected in changes in transcriptional activity and carcinogenesis are not understood. The expression levels were related to histological, clinical and laboratory parameters. We found that two of the mRNAs were markedly upregulated in two subgroups of ovarian carcinomas and also associated with stage and outcome. A major finding in this study was the strong upregulation of POLD2 in PDSC compared to control tissues and other Silmitasertib 1009820-21-6 histological subgroups of ovarian carcinomas examined. POLD2 is a subunit of the DNA polymerase delta complex, encoding a protein involved in DNA replication and repair. It is downregulated by the PTEN tumour suppressor gene, already known to be involved in ovarian carcinogenesis. In gliomas, a consistent pattern of chromosomal alterations were found involving altered regions which harboured seven “landscape genes” associated with patient survival, among these POLD2. KSP37 mRNA levels were clearly and distinctly regulated in early stage of CCC, another histological subgroup of ovarian cancer. KSP37 is identified as FGFBP2, a member of the fibroblast growth factor binding protein 2 family. It is expressed in cytotoxic T lymphocytes and natural killer cells, and is suggested to have a “cytotoxic potential” which so far has not been identified.